View ValuationCareRx 향후 성장Future 기준 점검 0/6CareRx 의 수익은 연간 54.6% 감소할 것으로 예상되는 반면, 연간 수익은 4% 로 증가할 것으로 예상됩니다. EPS는 연간 12.5% 만큼 쇠퇴할 것으로 예상됩니다.핵심 정보-54.6%이익 성장률-12.51%EPS 성장률Consumer Retailing 이익 성장9.3%매출 성장률4.0%향후 자기자본이익률n/a애널리스트 커버리지Good마지막 업데이트11 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 11CareRx Corporation announces Quarterly dividend, payable on July 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on July 09, 2026, ex-date on June 23, 2026 and record date on June 23, 2026.공시 • Apr 28CareRx Corporation to Report Q1, 2026 Results on May 06, 2026CareRx Corporation announced that they will report Q1, 2026 results After-Market on May 06, 2026공시 • Mar 17CareRx Corporation, Annual General Meeting, May 28, 2026CareRx Corporation, Annual General Meeting, May 28, 2026.공시 • Mar 10CareRx Corporation announces Quarterly dividend, payable on April 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on April 09, 2026, ex-date on March 19, 2026 and record date on March 19, 2026.공시 • Feb 25CareRx Corporation to Report Q4, 2025 Results on Mar 04, 2026CareRx Corporation announced that they will report Q4, 2025 results After-Market on Mar 04, 2026공시 • Dec 17CareRx Corporation announces Quarterly dividend, payable on January 21, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on January 21, 2026, ex-date on December 23, 2025 and record date on December 23, 2025.공시 • Oct 24CareRx Corporation to Report Q3, 2025 Results on Nov 03, 2025CareRx Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025공시 • Sep 17CareRx Corporation announces Quarterly dividend, payable on October 15, 2025CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on October 15, 2025, ex-date on September 23, 2025 and record date on September 23, 2025.공시 • Jul 21CareRx Corporation to Report Q2, 2025 Results on Jul 30, 2025CareRx Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025공시 • May 01CareRx Corporation to Report Q1, 2025 Results on May 07, 2025CareRx Corporation announced that they will report Q1, 2025 results at 7:00 AM, US Eastern Standard Time on May 07, 2025공시 • Mar 25CareRx Corporation, Annual General Meeting, Jun 05, 2025CareRx Corporation, Annual General Meeting, Jun 05, 2025.공시 • Feb 26CareRx Corporation to Report Q4, 2024 Results on Mar 05, 2025CareRx Corporation announced that they will report Q4, 2024 results at 7:00 AM, US Eastern Standard Time on Mar 05, 2025공시 • Oct 31CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024CareRx Corporation announced that they will report Q3, 2024 results at 7:00 AM, Eastern Standard Time on Nov 08, 2024공시 • Sep 05CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024CareRx Corporation announced that following an extensive executive search process, Suzanne Brand will be joining the Company in the role of Chief Financial Officer effective October 1, 2024. Ms. Brand is a highly accomplished executive, bringing a wealth of financial, healthcare and leadership experience. She joins CareRx from Teva Pharmaceuticals, a leading global manufacturer of quality generic and innovative pharmaceuticals, where she has held several senior finance roles since 2011, most recently serving as CFO of Teva Canada. Prior to joining Teva, Ms. Brand spent twelve years in finance at Wyeth Pharmaceuticals, a Pfizer company, where she held senior roles including as a Director, Commercial and Corporate Finance. She began her career as an auditor at PriceWaterhouseCoopers (PwC). Ms. Brand is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Science degree in Biology and Business from the University of Toronto.공시 • Aug 02CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024CareRx Corporation announced that they will report Q2, 2024 results at 7:00 AM, US Eastern Standard Time on Aug 08, 2024공시 • May 30CareRx Corporation Announces Board ChangesCareRx Corporation announced that as part of the Company's commitment to Board refreshment and to realign Board functions to match the Company's strategic focus on operational performance, Kevin Dalton, Chairman of the Board for the last six years, will be retiring as Chairman effectively immediately. Mr. Dalton will be succeeded by Jeff Watson, a current independent director of the Board. Mr. Dalton will be stepping into the role as Chair of the Compensation, Nominating and Governance Committee in place of Maria Perrella, who will continue to remain Chair of the Audit Committee. Mr. Watson has served on the Board of CareRx since 2023 and brings over three decades of experience in the healthcare industry, having most recently served as the President and CEO of Apotex from 2018 to 2023. Mr. Watson currently represents SK Capital Partners on two of their portfolio company boards for Apotex and Woodstock Sterile Solutions, and has previously served on numerous other boards, including as a board member and Chair of the Association for Accessible Medicines (AAM), Chair of the Canadian Generic Pharmaceutical Association (CGPA), and former Chair of the US Healthcare Distribution Alliance's (HDA) knowledge partner, the HDA Research Foundation.공시 • May 15CareRx Corporation Announces CFO TransitionCareRx Corporation announced that Andrew Mok will step down as Chief Financial Officer effective June 7, 2024, to pursue another employment opportunity. The Company is undertaking a search for a new CFO. Davide Pernarella, currently Vice President, Business Planning and Analysis at CareRx, will assume the role of Interim Chief Financial Officer following Mr. Mok's departure. Mr. Pernarella has worked at CareRx for over seven years in various roles with increasing responsibility, and has an intimate knowledge of the financial and business affairs of the Company. Prior to joining CareRx, he held roles in the Transaction Services and Assurance groups at KPMG Canada. Mr. Pernarella is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Commerce degree from the Rotman School of Management at the University of Toronto.공시 • Mar 15CareRx Corporation, Annual General Meeting, May 28, 2024CareRx Corporation, Annual General Meeting, May 28, 2024.공시 • Mar 08CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023CareRx Corporation reported goodwill and intangible assets impairment of $710,000 for the fourth quarter ended December 31, 2023.공시 • Mar 01CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024CareRx Corporation announced that they will report Q4, 2023 results at 7:00 AM, US Eastern Standard Time on Mar 07, 2024공시 • Nov 02CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023CareRx Corporation announced that they will report Q3, 2023 results at 7:00 AM, US Eastern Standard Time on Nov 08, 2023공시 • Aug 04CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023CareRx Corporation announced that they will report Q2, 2023 results at 7:00 AM, US Eastern Standard Time on Aug 10, 2023공시 • Jun 07Carerx Corporation Announces Director ChangesCareRx Corporation appointed Puneet Khanna and Jeff Watson as directors. Company announced that Matt Hills did not stand for re-election.공시 • Jan 19CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,963,000 Price\Range: CAD 2.7 Discount Per Security: CAD 0.162공시 • May 21CareRx Corporation announced that it has received CAD 63.250644 million in funding from Yorkville Asset Management Inc.On May 19, 2021, CareRx Corporation (TSX:CRRX) closed the transaction. The company issued a total of 12,524,880 subscription receipts for gross proceeds of CAD 63,250,644. The transaction included a portion of non-brokered placement from returning investor Yorkville Asset Management Inc. for 2,277,230 subscription receipts for proceeds of CAD 11,500,011.5 and brokered portion of 10,247,650 subscription receipts for proceeds of CAD 51,750,632.5.이익 및 매출 성장 예측OTCPK:CHHH.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CAD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028415830N/A312/31/2027406826N/A612/31/20263856163373/31/2026375272230N/A12/31/2025370262331N/A9/30/202536602130N/A6/30/2025366-22332N/A3/31/2025367-42836N/A12/31/2024367-53038N/A9/30/2024366-63138N/A6/30/2024367-72734N/A3/31/2024369-42332N/A12/31/2023371-51927N/A9/30/2023374-62533N/A6/30/2023378-73038N/A3/31/2023380-341629N/A12/31/2022382-34922N/A9/30/2022384-34-411N/A6/30/2022358-36-510N/A3/31/2022311-20-18N/A12/31/2021263-2307N/A9/30/2021212-2127N/A6/30/2021187-24-6-3N/A3/31/2021177-29-20N/A12/31/2020162-18-20N/A9/30/2020148-50-3-1N/A6/30/2020134-47-20N/A3/31/2020126-34-12N/A12/31/2019125-46N/A6N/A9/30/2019122-19N/A3N/A6/30/2019119-20N/A4N/A3/31/2019117-39N/A9N/A12/31/2018119-35N/A7N/A9/30/201885-27N/A14N/A6/30/201897-23N/A12N/A3/31/2018110-3N/A15N/A12/31/2017122-4N/A16N/A9/30/2017168-6N/A14N/A6/30/2017170-3N/A24N/A3/31/2017170-13N/A10N/A12/31/2016167-18N/A2N/A9/30/2016166-21N/A6N/A6/30/2016166-34N/A3N/A3/31/2016164-30N/A20N/A12/31/2015161-35N/A29N/A9/30/201527-47N/A28N/A6/30/201560-48N/A22N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CHHH.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -54.6%).수익 vs 시장: CHHH.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -54.6%).고성장 수익: CHHH.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다.수익 대 시장: CHHH.F 의 수익(연간 4%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: CHHH.F 의 수익(연간 4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CHHH.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YConsumer-retailing 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 00:22종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CareRx Corporation는 11명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kyle McPheeATB CormarkKyle McPheeATB Cormark Historical (Cormark Securities)Doug CooperBeacon Securities Limited8명의 분석가 더 보기
공시 • May 11CareRx Corporation announces Quarterly dividend, payable on July 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on July 09, 2026, ex-date on June 23, 2026 and record date on June 23, 2026.
공시 • Apr 28CareRx Corporation to Report Q1, 2026 Results on May 06, 2026CareRx Corporation announced that they will report Q1, 2026 results After-Market on May 06, 2026
공시 • Mar 17CareRx Corporation, Annual General Meeting, May 28, 2026CareRx Corporation, Annual General Meeting, May 28, 2026.
공시 • Mar 10CareRx Corporation announces Quarterly dividend, payable on April 09, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on April 09, 2026, ex-date on March 19, 2026 and record date on March 19, 2026.
공시 • Feb 25CareRx Corporation to Report Q4, 2025 Results on Mar 04, 2026CareRx Corporation announced that they will report Q4, 2025 results After-Market on Mar 04, 2026
공시 • Dec 17CareRx Corporation announces Quarterly dividend, payable on January 21, 2026CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on January 21, 2026, ex-date on December 23, 2025 and record date on December 23, 2025.
공시 • Oct 24CareRx Corporation to Report Q3, 2025 Results on Nov 03, 2025CareRx Corporation announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2025
공시 • Sep 17CareRx Corporation announces Quarterly dividend, payable on October 15, 2025CareRx Corporation announced Quarterly dividend of CAD 0.0200 per share payable on October 15, 2025, ex-date on September 23, 2025 and record date on September 23, 2025.
공시 • Jul 21CareRx Corporation to Report Q2, 2025 Results on Jul 30, 2025CareRx Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025
공시 • May 01CareRx Corporation to Report Q1, 2025 Results on May 07, 2025CareRx Corporation announced that they will report Q1, 2025 results at 7:00 AM, US Eastern Standard Time on May 07, 2025
공시 • Mar 25CareRx Corporation, Annual General Meeting, Jun 05, 2025CareRx Corporation, Annual General Meeting, Jun 05, 2025.
공시 • Feb 26CareRx Corporation to Report Q4, 2024 Results on Mar 05, 2025CareRx Corporation announced that they will report Q4, 2024 results at 7:00 AM, US Eastern Standard Time on Mar 05, 2025
공시 • Oct 31CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024CareRx Corporation announced that they will report Q3, 2024 results at 7:00 AM, Eastern Standard Time on Nov 08, 2024
공시 • Sep 05CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024CareRx Corporation announced that following an extensive executive search process, Suzanne Brand will be joining the Company in the role of Chief Financial Officer effective October 1, 2024. Ms. Brand is a highly accomplished executive, bringing a wealth of financial, healthcare and leadership experience. She joins CareRx from Teva Pharmaceuticals, a leading global manufacturer of quality generic and innovative pharmaceuticals, where she has held several senior finance roles since 2011, most recently serving as CFO of Teva Canada. Prior to joining Teva, Ms. Brand spent twelve years in finance at Wyeth Pharmaceuticals, a Pfizer company, where she held senior roles including as a Director, Commercial and Corporate Finance. She began her career as an auditor at PriceWaterhouseCoopers (PwC). Ms. Brand is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Science degree in Biology and Business from the University of Toronto.
공시 • Aug 02CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024CareRx Corporation announced that they will report Q2, 2024 results at 7:00 AM, US Eastern Standard Time on Aug 08, 2024
공시 • May 30CareRx Corporation Announces Board ChangesCareRx Corporation announced that as part of the Company's commitment to Board refreshment and to realign Board functions to match the Company's strategic focus on operational performance, Kevin Dalton, Chairman of the Board for the last six years, will be retiring as Chairman effectively immediately. Mr. Dalton will be succeeded by Jeff Watson, a current independent director of the Board. Mr. Dalton will be stepping into the role as Chair of the Compensation, Nominating and Governance Committee in place of Maria Perrella, who will continue to remain Chair of the Audit Committee. Mr. Watson has served on the Board of CareRx since 2023 and brings over three decades of experience in the healthcare industry, having most recently served as the President and CEO of Apotex from 2018 to 2023. Mr. Watson currently represents SK Capital Partners on two of their portfolio company boards for Apotex and Woodstock Sterile Solutions, and has previously served on numerous other boards, including as a board member and Chair of the Association for Accessible Medicines (AAM), Chair of the Canadian Generic Pharmaceutical Association (CGPA), and former Chair of the US Healthcare Distribution Alliance's (HDA) knowledge partner, the HDA Research Foundation.
공시 • May 15CareRx Corporation Announces CFO TransitionCareRx Corporation announced that Andrew Mok will step down as Chief Financial Officer effective June 7, 2024, to pursue another employment opportunity. The Company is undertaking a search for a new CFO. Davide Pernarella, currently Vice President, Business Planning and Analysis at CareRx, will assume the role of Interim Chief Financial Officer following Mr. Mok's departure. Mr. Pernarella has worked at CareRx for over seven years in various roles with increasing responsibility, and has an intimate knowledge of the financial and business affairs of the Company. Prior to joining CareRx, he held roles in the Transaction Services and Assurance groups at KPMG Canada. Mr. Pernarella is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA) and holds a Bachelor of Commerce degree from the Rotman School of Management at the University of Toronto.
공시 • Mar 15CareRx Corporation, Annual General Meeting, May 28, 2024CareRx Corporation, Annual General Meeting, May 28, 2024.
공시 • Mar 08CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023CareRx Corporation reported goodwill and intangible assets impairment of $710,000 for the fourth quarter ended December 31, 2023.
공시 • Mar 01CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024CareRx Corporation announced that they will report Q4, 2023 results at 7:00 AM, US Eastern Standard Time on Mar 07, 2024
공시 • Nov 02CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023CareRx Corporation announced that they will report Q3, 2023 results at 7:00 AM, US Eastern Standard Time on Nov 08, 2023
공시 • Aug 04CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023CareRx Corporation announced that they will report Q2, 2023 results at 7:00 AM, US Eastern Standard Time on Aug 10, 2023
공시 • Jun 07Carerx Corporation Announces Director ChangesCareRx Corporation appointed Puneet Khanna and Jeff Watson as directors. Company announced that Matt Hills did not stand for re-election.
공시 • Jan 19CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,963,000 Price\Range: CAD 2.7 Discount Per Security: CAD 0.162
공시 • May 21CareRx Corporation announced that it has received CAD 63.250644 million in funding from Yorkville Asset Management Inc.On May 19, 2021, CareRx Corporation (TSX:CRRX) closed the transaction. The company issued a total of 12,524,880 subscription receipts for gross proceeds of CAD 63,250,644. The transaction included a portion of non-brokered placement from returning investor Yorkville Asset Management Inc. for 2,277,230 subscription receipts for proceeds of CAD 11,500,011.5 and brokered portion of 10,247,650 subscription receipts for proceeds of CAD 51,750,632.5.